F M Investments LLC Acquires Shares of 81,343 Savara Inc (NASDAQ:SVRA)

F M Investments LLC bought a new position in shares of Savara Inc (NASDAQ:SVRA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 81,343 shares of the company’s stock, valued at approximately $250,000.

Other large investors have also modified their holdings of the company. Cibc World Markets Corp acquired a new position in Savara during the fourth quarter worth about $33,000. KLP Kapitalforvaltning AS purchased a new position in Savara in the 4th quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in shares of Savara during the 3rd quarter worth approximately $67,000. BNP Paribas Financial Markets boosted its holdings in shares of Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after purchasing an additional 18,534 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after purchasing an additional 4,732 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ SVRA opened at $2.92 on Friday. The stock has a fifty day simple moving average of $2.72 and a 200-day simple moving average of $3.13. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $504.09 million, a PE ratio of -6.79 and a beta of 0.52. Savara Inc has a twelve month low of $2.26 and a twelve month high of $5.33.

Savara (NASDAQ:SVRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. Equities analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SVRA has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Savara in a research note on Friday, March 28th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th. Finally, Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.